Transplant International (Jan 2025)
No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin
- Nathalie Grall,
- Nathalie Grall,
- Maksud Assadi,
- Marina Esposito-Farese,
- Brice Lortat-Jacob,
- Sébastien Tanaka,
- Sébastien Tanaka,
- Enora Atchade,
- Jonathan Messika,
- Jonathan Messika,
- Jonathan Messika,
- Vincent Bunel,
- Hervé Mal,
- Hervé Mal,
- Pierre Mordant,
- Pierre Mordant,
- Pierre Mordant,
- Yves Castier,
- Yves Castier,
- Bastien Garnier,
- Signara Gueye,
- Marie Petitjean,
- Erick Denamur,
- Laurence Armand-Lefevre,
- Laurence Armand-Lefevre,
- Charles Burdet,
- Philippe Montravers,
- Philippe Montravers,
- Alexy Tran-Dinh,
- Alexy Tran-Dinh
Affiliations
- Nathalie Grall
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Bactériologie, Paris, France
- Nathalie Grall
- INSERM UMR 1137 IAME, Université Paris Cité, Paris, France
- Maksud Assadi
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, France
- Marina Esposito-Farese
- Université Paris Cité, AP-HP, Hôpital Bichat, Département d’Epidémiologie et Recherche Clinique, Paris, France
- Brice Lortat-Jacob
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, France
- Sébastien Tanaka
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, France
- Sébastien Tanaka
- Réunion Island University, INSERM U1188 Diabetes Atherothrombosis Réunion Indian OCean (DéTROI), CYROI Plateform, Saint-Denis de La Réunion, France
- Enora Atchade
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, France
- Jonathan Messika
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Pneumologie B et Transplantation Pulmonaire, Paris, France
- Jonathan Messika
- INSERM UMR 1152 PHERE, Université Paris Cité, Paris, France
- Jonathan Messika
- Paris Transplant Group, Paris, France
- Vincent Bunel
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Pneumologie B et Transplantation Pulmonaire, Paris, France
- Hervé Mal
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Pneumologie B et Transplantation Pulmonaire, Paris, France
- Hervé Mal
- INSERM UMR 1152 PHERE, Université Paris Cité, Paris, France
- Pierre Mordant
- INSERM UMR 1152 PHERE, Université Paris Cité, Paris, France
- Pierre Mordant
- Paris Transplant Group, Paris, France
- Pierre Mordant
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Chirurgie Vasculaire, Thoracique et Transplantation Pulmonaire, Paris, France
- Yves Castier
- INSERM UMR 1152 PHERE, Université Paris Cité, Paris, France
- Yves Castier
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Chirurgie Vasculaire, Thoracique et Transplantation Pulmonaire, Paris, France
- Bastien Garnier
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, France
- Signara Gueye
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Bactériologie, Paris, France
- Marie Petitjean
- INSERM UMR 1137 IAME, Université Paris Cité, Paris, France
- Erick Denamur
- INSERM UMR 1137 IAME, Université Paris Cité, Paris, France
- Laurence Armand-Lefevre
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Bactériologie, Paris, France
- Laurence Armand-Lefevre
- INSERM UMR 1137 IAME, Université Paris Cité, Paris, France
- Charles Burdet
- Université Paris Cité, AP-HP, Hôpital Bichat, Département d’Epidémiologie et Recherche Clinique, Paris, France
- Philippe Montravers
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, France
- Philippe Montravers
- INSERM UMR 1152 PHERE, Université Paris Cité, Paris, France
- Alexy Tran-Dinh
- Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, France
- Alexy Tran-Dinh
- 0INSERM UMR 1148 LVTS, Université Paris Cité, Paris, France
- DOI
- https://doi.org/10.3389/ti.2024.13545
- Journal volume & issue
-
Vol. 37
Abstract
Secondary prophylaxis using inhaled colistin (IC) was implemented to prevent recurrences of Pseudomonas aeruginosa or extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) pneumonia during the postoperative intensive care unit (ICU) stay after lung transplantation (LT). We evaluated the risk of emergence of colistin resistance in the respiratory tract during secondary IC prophylaxis. We conducted a prospective, single-centre, observational study of all adult patients who underwent LT between 1 July 2018 and 30 June 2019. IC was started and continued for at least 90 days for P. aeruginosa or ESBL-PE pneumonia. During the 90 days following LT, all respiratory samples were routinely tested for the presence of GNB of reduced susceptibility to colistin. Twenty-seven (38.6%) of the 70 included patients received IC. Among the 867 respiratory samples tested, IC did not promote the emergence of bacterial species with natural or acquired resistance to colistin (incidence-rate ratio of 0.21 [0.03–1.58], p = 0.13 and 1.68 [0.55–5.12], p = 0.37, respectively). Our study suggests no association between the use of IC and an increased risk of colistin resistance in the respiratory tract within 90 days of LT.
Keywords
